Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.
about
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Abacavir/lamivudine combination in the treatment of HIV: a review.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Immune-mediated attenuation of HIV-1Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationHypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionTargeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptaseTemplate usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials
P2860
Q28478993-8ACAC4A2-3728-4FBD-BFF0-C45E162E297FQ28533996-999CA751-D5C5-4302-9D24-560F89ADE42CQ33681279-47EEB6FF-ABC0-401F-8BAB-143D0988F5B9Q33715435-743B050A-FF6D-4CF1-B50E-3E3D3D46574AQ33889635-F126BC7E-B7F4-45D4-BCA2-F4277616194CQ33927293-87E36458-4E68-4EA8-B157-C1ECF1616F88Q34249966-D004D8E8-156B-40E0-84BE-E9E281EE6A90Q34573897-59EC8196-04EA-4150-844A-605594881620Q35473551-6C680489-563B-4947-82F5-103ECFD7FF6DQ35607740-800FBFC5-40E6-43D3-96D3-5035DE6A550AQ35636514-8C86B4CD-0343-476A-8C1B-4E8F5957F914Q35798108-1B4C6BBA-2744-4F9A-9F23-1EFBAA109FDAQ36386787-E821A5F5-F1B7-465A-A7F0-26854F18A8A6Q36438778-05EDAB9E-C7BB-48D4-A1E7-51F959374F26Q36964321-9A9FC082-C87D-4175-B0FF-862C6CA5F962Q37021431-35EBCCED-E29F-443A-A271-85750E0E79D0Q37071435-C083C173-8B72-4D70-8E5F-8E156834AC32Q37332192-54EFBF50-3405-4BB9-B22D-E08068AEDD29Q37409900-EA453468-03F5-48E8-A2E4-F9F930302248Q38356685-B30488DF-E933-4EE3-8378-BA6B8C11577EQ39724626-8D9A8F81-050B-43D8-9ED6-6C9BE469A8FBQ39895796-0485AF06-B55E-491E-8A1B-47ED611FCCCBQ41788281-D2086D70-D3A5-4CFD-96E5-4FBF365143A0Q41862836-6A803A60-DB5F-4F30-9747-8B7C1E27DB4FQ43077557-4B8E52D8-0886-4FC3-8E43-91C8D6F77686Q46718140-73B81BDA-5215-43E6-8637-1FA682C9C39CQ54596202-6032F532-08B0-4C53-9A72-FCA5E42DCCBFQ57207278-E61ED6D3-A98C-4F56-BB23-6F0052082B88
P2860
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Diminished efficiency of HIV-1 ...... 84V drug resistance mutations.
@en
type
label
Diminished efficiency of HIV-1 ...... 84V drug resistance mutations.
@en
prefLabel
Diminished efficiency of HIV-1 ...... 84V drug resistance mutations.
@en
P2093
P1433
P1476
Diminished efficiency of HIV-1 ...... 84V drug resistance mutations.
@en
P2093
Cédric F Invernizzi
Fernando A Frankel
Mark A Wainberg
Maureen Oliveira
P304
P356
10.1097/QAD.0B013E3280187505
P407
P577
2007-03-01T00:00:00Z